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Abstract
Background: Gene therapy with plasmid DNA is emerging as a promising strategy for the
treatment of many diseases. One of the major obstacles to such therapy is the poor transfection
efficiency of DNA in vivo.
Methods: In this report, we employed a very low power, near-infrared femtosecond laser
technique to enhance the transfection efficiency of intradermally and intratumorally administered
DNA plasmid.
Results: We found that femtosecond laser treatment can significantly enhance the delivery of
DNA into the skin and into established tumors in mice. In addition, we found that both laser power
density as well as duration of laser treatment are critical parameters for augmenting DNA
transfection efficiency. The femtosecond laser technique employs a relatively unfocused laser beam
that maximizes the transfected area, minimizes damage to tissue and simplifies its implementation.
Conclusion: This femtosecond new laser technology represents a safe and innovative technology
for enhancing DNA gene transfer in vivo.
Background
Gene therapy continues to evolve as an attractive
approach for the treatment of many diseases (for reviews,
see [1-11]). In particular, the use of plasmid DNA for gene
therapy has several advantages which can circumvent the
limitations and potential risks associated with viral vec-
tor-based DNA delivery. It is relatively safe, stable, and
inexpensive to manufacture, making it attractive for appli-
cation in the clinical arena. Furthermore, in contrast to
viral vectors, DNA vaccines do not elicit anti-vector
immune responses in the vaccinated patient, and, there-
fore, are well suited for indications likely to require mul-
tiple administrations in order to achieve and maintain
target immune responses.
The ideal approach for enhancing DNA vaccine potency is
by improving the transfection efficiency with minimal tis-
sue damage. Several physical techniques including elec-
Published: 1 April 2009
Journal of Biomedical Science 2009, 16:36 doi:10.1186/1423-0127-16-36
Received: 10 November 2008
Accepted: 1 April 2009
This article is available from: http://www.jbiomedsci.com/content/16/1/36
© 2009 Tsen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7
(page number not for citation purposes)
The cost of publication in Journal of Biomedical Science
is bourne by the National Science Council, Taiwan.
Journal of Biomedical Science 2009, 16:36 http://www.jbiomedsci.com/content/16/1/36troporation and ultrasound have been employed in an
effort to improve gene transfection efficiency. However,
several safety concerns have been raised with the applica-
tion of these approaches in humans (for reviews, see
[12,13]). Therefore, continued exploration for new meth-
ods of enhancing DNA transfection efficiency while min-
imizing side effects is essential for generating potent DNA
vaccination strategies and also for gene therapy using plas-
mid DNA.
Femtosecond laser treatment represents a novel and
attractive method for in vivo gene delivery because the
lasers are convenient to operate, relatively non-invasive,
and have been shown to significantly enhance gene trans-
fection efficiency without detectable tissue damage in
mice [14,15]. They have been applied toward in vitro
genetic modification of cells (for a review, see [16]) and
have recently been found to improve intradermal and
intramuscular delivery of DNA in mice [14,15]. Therefore,
in the current study, we employed femtosecond laser
treatment in an effort to improve the transfection effi-
ciency of DNA encoding luciferase that was administered
intradermally as well as intratumorally in mice, with the
hope of finding an innovative technology that may be
used both for DNA vaccination as well as for plasmid
DNA gene therapy in the clinical setting.
Methods
Laser setup
An infrared femtosecond fiber laser system (IMRA μJewel
D-400) that provides 500 fs duration pulses at ~1043 nm
wavelength with repetition rate 200 kHz was used to irra-
diate mice (IMRA America, Inc.; Ann Arbor, MI, USA). The
laser beam was transmitted through a focal lens to allow
tuning of laser power density by varying target distance
from the focal lens, and then through a small (0.5 cm
diameter) hole in a wooden block to allow optimal align-
ment of the laser beam with the DNA injection site on the
mice (see Figure 1).
Plasmids and Cell Lines
The construct encoding firefly luciferase, termed pcDNA3-
Luc, was a kind gift from Dr. Hyam Levitsky, Johns Hop-
kins University. TC-1, an E6/E7-expressing tumor cell line,
was derived from primary epithelial cells of C57BL/6 mice
and co-transformed with HPV-16 E6 and E7 and c-Ha-ras
oncogenes as previously described [17].
Intradermal gene transfection experiments
C57BL/6 mice (3 per group) were anesthetized by iso-
fluorane inhalation, shaved, and injected intradermally
(depth = 0.5 mm) with 10 μg/mouse of pcDNA3-Luc in a
total volume of 50 μl. This was followed immediately by
either femtosecond laser treatment at a laser power den-
sity of 0.04 GW/cm2 for 80 sec or no treatment.
Nude mice were similarly injected intradermally with 10
μg/mouse of pcDNA3-Luc in a total volume of 50 μl, fol-
lowed immediately by either femtosecond laser treatment
at various laser power densities for 80 sec. In addition, a
group of nude mice received treatment at a laser power
density of 0.04 GW/cm2 for different laser treatment time
durations. Nude mice without laser treatment were used
as control. The intensity of the luminescence in the mice
was monitored by bioluminescent imaging 16 hours after
DNA administration.
Intratumoral gene transfection experiments
Female C57BL/6 mice (7 per group) were subcutaneously
challenged in the abdominal wall with 1 × 105 TC-1 tumor
cells/mouse. When tumors reached a diameter of ~0.7 cm,
the mice were anesthetized by isoflurane inhalation,
shaved, and injected intratumorally (depth = 1.0 mm)
with a single dose of 10 μg/mouse of pcDNA3-Luc in a
total volume of 50 μl, which was followed immediately by
either femtosecond laser treatment at a laser power den-
sity of 0.04 GW/cm2 for 110 sec or no treatment. The
intensity of the luminescence in the mice was monitored
by bioluminescent imaging 16 hours after DNA injection.
In vivo bioluminescence imaging
To monitor luminescent intensity, the mice were injected
with 0.2 ml of 15 mg/ml beetle luciferin (potassium salt,
Promega) per mouse. After 10 minutes, the mice were
imaged using the IVIS 200 system (Xenogen Corp,
Alameda, CA). An integration time of 1 minute was used
for luminescence image acquisition.
Statistical analysis
All data expressed as means ± SE are representative of at
least two different experiments. Comparisons between
individual data points were made using the Student's t
test. A p value < 0.05 was considered statistically signifi-
cant.
Results
Femtosecond lasers enhance the transfection efficiency of 
luciferase-encoding plasmid DNA administered 
intradermally
In order to determine if femtosecond laser treatment can
improve the transfection efficiency of intradermally
administered luciferase-encoding DNA plasmid, female
C57BL/6 mice (3 per group) were injected intradermally
with the pcDNA3-luciferase plasmid, followed immedi-
ately by femtosecond laser treatment at the injection site.
As shown in Figure 2, we found that mice receiving fem-
tosecond laser treatment after DNA administration gener-
ated significantly enhanced luciferase gene expression
compared to mice injected with DNA without laser treat-
ment (p < 0.05). Thus, our data indicate that femtosecondPage 2 of 7
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intradermally injected DNA.
Enhancement in transfection efficiency using femtosecond 
laser treatment depends on the laser power density and 
duration of laser treatment
In order to evaluate the maximum enhancement of trans-
fection efficiency achievable with the application of fem-
tosecond laser treatment with intradermally administered
DNA, we modulated the laser power density and the dura-
tion of laser treatment. C57BL/6 mice (3 per group) were
injected intradermally with the pcDNA3-luciferase plas-
mid, which was followed immediately by femtosecond
laser treatment at the injection site using various laser
power densities and time durations of laser treatment. As
shown in Figure 3A, at a constant duration of laser treat-
ment of 80 seconds, we found that mice receiving laser
treatment at a laser power density of 0.04 GW/cm2 gener-
ated the highest transfection efficiency compared to mice
treated at different laser power densities. This laser power
density corresponds to a laser energy of 2.6 μJ/pulse with
a spot size of 4 mm. Furthermore, at a constant laser
power density constant of 0.04 GW/cm2, we found that
mice receiving laser treatment for a duration of 80 seconds
generated the highest transfection efficiency compared to
mice treated for different durations (Figure 3B). Treat-
ment of DNA-administered mice with laser for 80 sec at a
laser power density of 0.04 GW/cm2 resulted in the high-
est (up to 23-fold) enhancement of gene expression com-
pared to mice without laser treatment (see Figure 3).
These results indicate that the laser power densities as well
as the duration of laser treatment are critical factors affect-
Schematic diagram depicting the femtosecond laser setup for treatment of miceFigure 1
Schematic diagram depicting the femtosecond laser setup for treatment of mice. The laser beam was transmitted 
through a focal lens to allow tuning of laser power density by varying target distance from the focal lens. The beam was trans-
mitted through a small 0.5 cm diameter hole in a wooden block to allow for optimal alignment of the laser beam with the DNA 
injection site on the mice.Page 3 of 7
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mally administered DNA using femtosecond laser
treatment.
Femtosecond laser treatment can enhance the 
transfection efficiency of luciferase-expressing DNA 
injected intratumorally
To determine if femtosecond laser treatment can be used
to enhance the transfection efficiency of DNA adminis-
tered intratumorally, we performed tumor gene transfec-
tion experiments. Female C57BL/6 mice were challenged
subcutaneously with 1 × 105 of TC-1 tumor cells/mouse in
the right leg. When tumors reached a diameter of ~0.7 cm,
mice were injected intratumorally with pcDNA3-Luc
DNA, followed by either femtosecond laser treatment for
110 seconds at a laser power density of 0.04 GW/cm2 or
no treatment. A laser treatment time duration of 110 sec-
onds was chosen based on preliminary experiments (data
not shown). As shown in Figure 4, we found that tumor-
bearing mice injected intratumorally with DNA followed
by laser treatment had significantly increased luciferase
expression 16 hours after injection compared to mice
injected with DNA without laser treatment (p ≤ 0.020).
Thus, our data indicate that treatment with femtosecond
lasers after DNA administration can enhance the transfec-
tion efficiency of DNA injected into tumors.
Discussion
In this study, we found that femtosecond lasers can signif-
icantly enhance DNA transfection efficiency into the skin
and into established tumors in mice, and that both the
laser power density used as well as the laser treatment
duration are important parameters that determine the
enhancement in gene transfection afforded by the femto-
second laser. Using these parameters, we have optimized
the laser system for maximum intradermal and intratu-
moral DNA transfection efficiency.
Our data are consistent with previous reports that femto-
second lasers can enhance intradermal DNA delivery [15].
However, ours is the first report demonstrating the use of
femtosecond lasers to enhance intratumoral DNA deliv-
ery. Compared to these previous studies, our femtosecond
laser treatment employs significantly reduced laser focus-
ing, which offers several advantages. First, it greatly
increases the transfected area and thus maximizes the
number of cells that are transfected. Second, the laser
energy is greatly reduced, thereby minimizing damage to
Characterization of luciferase expression in mice injected intradermally with luciferase expressing DNA with or without laser tre tmentFigure 2
Characterization of luciferase expression in mice injected intradermally with luciferase expressing DNA with 
or without laser treatment. C57BL/6 mice (3 per group) were injected intradermally with 10 μg/mouse pcDNA3-luc in 50 
μl volume. Immediately after DNA injection, the injected mice were treated with laser for 80 sec at a laser power density of 
0.04 GW/cm2. Mice were imaged 16 hours after DNA injection using the IVIS Imaging System Series 200. Bioluminescence sig-
nals were acquired for 1 minute. (A) Representative luminescence images of injected mice with or without laser treatment. 
(B) Bar graph showing relative luciferase activity for both groups of mice using data from all mice tested (p < 0.05).Page 4 of 7
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tem to implement. Such characteristics make this tech-
nique especially promising for future clinical
applications.
Our results suggest that femtosecond laser treatment may
improve the efficacy of DNA vaccination and/or gene
therapy using plasmid DNA. Such a laser technology can
be used to deliver DNA encoding antitumor genes includ-
ing proapoptotic, immunostimulatory, and/or antiang-
iogenic factors to effect eradication of tumors through
apoptosis, immune-mediated mechanisms, and nutrient
deprivation. In future studies, it will be important to
explore the employment of laser treatment in combina-
tion with gene therapy using plasmid DNA encoding
these factors for the control of disease in preclinical mod-
els.
However, the eventual clinical translation of the femtosec-
ond laser technique would require several important con-
siderations. Although our results demonstrated
significantly improved transfection of subcutaneous
tumors using laser treatment, many tumors clinically are
less accessible and are located deep within body cavities.
Novel adaptations must therefore be made to make these
tumors accessible, such as the employment of lasers with
longer wavelengths that have greater penetration depth in
tissue, or percutaneous laser delivery devices which can
allow laser delivery to deeper structures through mini-
mally invasive means. In addition, the size of the laser
beam can be further increased to allow the transfection of
larger numbers of tumor cells, and the portability of the
laser system must be improved in order to make it more
clinically accessible.
Conclusion
Our data provide a platform on which a new femtosecond
laser-based DNA delivery strategy can be developed. We
have determined that laser power density and duration of
laser treatment play a crucial role for optimizing the trans-
fection efficiency of DNA, and that these parameters vary
depending on the location of delivery (intradermal versus
intratumoral). Further optimization of these parameters
will be necessary for future application of the femtosec-
ond laser system in humans and in a broader range of
tumor sites. It is our hope that such a technology will aid
Characterization of optimal laser power density and duration of laser treatment for maximum enhancement in transfection efficiencyFigure 3
Characterization of optimal laser power density and duration of laser treatment for maximum enhancement 
in transfection efficiency. Nude mice were injected intradermally with 10 μg/mouse pcDNA3-luc in 50 μl volume and 
immediately treated with femtosecond laser at various laser power densities and with various laser treatment time durations. 
Mice were imaged 16 hours after DNA injection using the IVIS Imaging System Series 200. Bioluminescence signals were 
acquired for 1 minute. Laser was first optimized for laser power density, and then for laser treatment time. Untreated mice 
were used as control. (A) Bar graph showing relative luciferase activity in mice receiving laser treatment at different laser 
power densities, while keeping laser treatment time duration constant at 80 sec. (B) Bar graph showing relative luciferase 
activity in mice receiving laser treatment at different laser treatment time durations, while keeping laser power density at 0.04 
GW/cm2.Page 5 of 7
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the treatment of human disease.
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